Who says they aren’t following? The bigs won’t publicize until they have their position and right now they can’t get in due to self imposed restrictions designed to mitigate risk for their clients. Timing is everything for them too as big pharma has been good for producing good returns for them so cutting them off to move in a different or more restricted direction will only come at the officially derisked time. Current longs have had no such restrictions placed on them but in this case the “risk” of not following others is in the depth of one’s own due diligence (confidence factor) and ability to wait (time and opportunity cost). Those who run out of confidence or time sell. Those who wait find ways to do so even if needing to complain about waiting to release some frustration. A more constructive approach might be to write to a representative about how “the process” is affecting patients which might be them or someone they love someday. Best wishes.
Market Data 
Markets 
AI
